Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins

Executive Summary

Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
Advertisement

Related Content

FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff
PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff
FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
First-Cycle Approvals May Rise For Second Consecutive Year – Parexel Report
Complete Response, Harmonization, INDs Rank On FDA Regulatory Agenda
FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III
FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III
Advertisement
UsernamePublicRestriction

Register

PS047618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel